The molecular basis of the antidiabetic action of quercetin in cultured skeletal muscle cells and hepatocytes

Pharmacognosy Magazine

Volumn 11, Issue 41, 2015, Pages 74-81

  Eid, Hoda M ^a,b,c   Nachar, Abir ^a,b   Thong, Farah ^d   Sweeney, Gary ^d   Haddad, Pierre S ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

^c BENI SUEF UNIVERSITY   (Egypt)

^d YORK UNIVERSITY   (Canada)

Author keywords

adenosine monophosphate activated protein kinase; Akt; glucose transporter; glucose 6 phosphatase; glycogen synthase; insulin resistance; Quercetin; type 2 diabetes mellitus

Indexed keywords

ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; ADENOSINE PHOSPHATE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE; INSULIN; PROTEIN KINASE; QUERCETIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIDIABETIC ACTIVITY; ARTICLE; CELL ACTIVITY; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CULTURE; MOUSE; MUSCLE CELL; MUSCLE FIBER CULTURE; MYOTUBE; NONHUMAN; PROTEIN CONTENT; SKELETAL MUSCLE;

EID: 84961288585     PISSN: 09731296     EISSN: 09764062     Source Type: Journal    
DOI: 10.4103/0973-1296.149708     Document Type: Article

References (42)

1. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-Activated receptor agonists provide a rational therapeutic approach. J Clinl Endocrinol Metab 2004;89:463-78.
2. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40.
3. IDF Diabetes Atlas, Sixth edition. Available from: http://www.idf.org/sites/default/files/ EN-6E-Atlas-Full-0.pdf [Last accessed on 2014 Sep 3]
4. Kasbia GS. Functional foods and nutraceuticals in the management of obesity. Nutr Food Sci 2005;35:344-52.
5. Kandaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, et al. The antitumor activities of flavonoids. In Vivo 2005;19:895-909.
6. Teixeira S, Siquet C, Alves C, Boal I, Marques MP, Borges F, et al. Structure-property studies on the antioxidant activity of flavonoids present in diet. Free Radic Biol Med 2005;39:1099-108.
7. Cushnie TP, Lamb AJ. Recent advances in understanding the antibacterial properties of flavonoids. Int J Antimicrob Agents 2011;38:99-107.
8. Emerit I, Huang CY, Serejo F, Filipe P, Fernandes A, Costa A, et al. Oxidative stress in chronic hepatitis C: A preliminary study on the protective effects of antioxidant flavonoids. Hepatogastroenterology 2005;52:530-6.
9. Orhan DD, Ozcelik B, Ozgen S, Ergun F. Antibacterial, antifungal, and antiviral activities of some flavonoids. Microbiol Res 2010;165:496-504.
10. Gonzalez-Gallego J, Sanchez-Campos S, Tunon MJ. Anti-inflammatory properties of dietary flavonoids. Nutr Hosp 2007;22:287-93.
11. Cook NC, Samman S. Flavonoids: Chemistry, metabolism, cardioprotective effects, and dietary sources. J Nutr Biochem 1996;7:66-76.
12. Lamson DW, Brignall MS. Antioxidants and cancer, part 3: Quercetin. Altern Med Rev 2000;5:196-208.
13. Zheng SY, Li Y, Jiang D, Zhao J, Ge JF. Anticancer effect and apoptosis induction by quercetin in the human. Mol Med Rep 2012;5:822-6.
14. Kleemann R, Verschuren L, Morrison M, Zadelaar S, van Erk MJ, Wielinga PY, et al. Anti-inflammatory, anti-proliferative and anti-Atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 2011;218:44-52.
15. Beretz A, Cazenave JP, Anton R. Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: Structure-Activity relationships. Agents Actions 1982;12:382-7.
16. Perez-Vizcaino F, Duarte J, Jimenez R, Santos-Buelga C, Osuna A. Antihypertensive effects of the flavonoid quercetin. Pharmacol Rep 2009;61:67-75.
17. Yamamoto Y, Oue E. Antihypertensive effect of quercetin in rats fed with a high-fat high-sucrose diet. Biosci Biotechnol Biochem 2006;70:933-9.
18. Kim MR, Lee JY, Lee HH, Aryal DK, Kim YG, Kim SK, et al. Antioxidative effects of quercetin-glycosides isolated from the flower buds of Tussilago farfara L. Food Chem Toxicol 2006;44:1299-307.
19. Manzano S, Williamson G. Polyphenols and phenolic acids from strawberry and apple decrease glucose uptake and transport by human intestinal Caco-2 cells. Mol Nutr Food Res 2010;54:1773-80.
20. Youl E, Bardy G, Magous R, Cros G, Sejalon F, Virsolvy A, et al. Quercetin potentiates insulin secretion and protects INS-1 pancreatic beta-cells against oxidative damage via the ERK1/2 pathway. Br J Pharmacol 2010;161:799-814.
21. Kim JH, Kang MJ, Choi HN, Jeong SM, Lee YM, Kim JI. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr Res Pract 2011;5:107-11.
22. Coskun O, Kanter M, Korkmaz A, Oter S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol Res 2005;51:117-23.
23. Eid HM, Martineau LC, Saleem A, Muhammad A, Vallerand D, Benhaddou-Andaloussi A, et al. Stimulation of AMP-Activated protein kinase and enhancement of basal glucose uptake in muscle cells by quercetin and quercetin glycosides, active principles of the antidiabetic medicinal plant Vaccinium vitis-idaea. Mol Nutr Food Res 2010;54:991-1003.
24. Pelletier A, Joly E, Prentki M, Coderre L. Adenosine 5-monophosphate-Activated protein kinase and p38 mitogen-Activated protein kinase participate in the stimulation of glucose uptake by dinitrophenol in adult cardiomyocytes. Endocrinology 2005;146:2285-94.
25. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: An overview. Clin Sci (Lond) 2012;122:253-70.
26. Song GY, Gao Y, Wang C, Hu SG, Wang J, Qu DM, et al. Rosiglitazone reduces fatty acid translocase and increases AMPK in skeletal muscle in aged rats: A possible mechanism to prevent high-fat-induced insulin resistance. Chin Med J (Engl) 2010;123:2384-91.
27. Krssak M, Brehm A, Bernroider E, Anderwald C, Nowotny P, Dalla Man C, et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 2004;53:3048-56.
28. Somwar R, Koterski S, Sweeney G, Sciotti R, Djuric S, Berg C, et al. A dominant-negative p38 MAPK mutant and novel selective inhibitors of p38 MAPK reduce insulin-stimulated glucose uptake in 3T3-L1 adipocytes without affecting GLUT4 translocation. J Biol Chem 2002;277:50386-95.
29. Niu W, Huang C, Nawaz Z, Levy M, Somwar R, Li D, et al. Maturation of the regulation of GLUT4 activity by p38 MAPK during L6 cell myogenesis. J Biol Chem 2003;278:17953-62.
30. Heishi M, Ichihara J, Teramoto R, Itakura Y, Hayashi K, Ishikawa H, et al. Global gene expression analysis in liver of obese diabetic db/db mice treated with metformin. Diabetologia 2006;49:1647-55.
31. Lau CH, Chan CM, Chan YW, Lau KM, Lau TW, Lam FC, et al. In vitro antidiabetic activities of five medicinal herbs used in Chinese medicinal formulae. Phytother Res 2008;22:1384-8.
32. Simpson RJ. Quantifying protein by bicinchoninic Acid. CSH Protoc 2008;2008:pdb.prot4722.
33. Franch J, Aslesen R, Jensen J. Regulation of glycogen synthesis in rat skeletal muscle after glycogen-depleting contractile activity: Effects of adrenaline on glycogen synthesis and activation of glycogen synthase and glycogen phosphorylase. Biochem J 1999;344:231-5.
34. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787-835, ix.
35. Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, Kalhan SC. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 1996;98:378-85.
36. James DE, Strube M, Mueckler M. Molecular cloning and characterization of an insulin-regulatable glucose transporter. Nature 1989;338:83-7.
37. Hayashi T, Hirshman MF, Fujii N, Habinowski SA, Witters LA, Goodyear LJ. Metabolic stress and altered glucose transport: Activation of AMP-Activated protein kinase as a unifying coupling mechanism. Diabetes 2000;49:527-31.
38. Gregus Z, Nemeti B. Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors. Toxicol Sci 2007;100:44-53.
39. Jakobs S, Fridrich D, Hofem S, Pahlke G, Eisenbrand G. Natural flavonoids are potent inhibitors of glycogen phosphorylase. Mol Nutr Food Res 2006;50:52-7.
40. Greenberg CC, Jurczak MJ, Danos AM, Brady MJ. Glycogen branches out: New perspectives on the role of glycogen metabolism in the integration of metabolic pathways. Am J Physiol Endocrinol Metab 2006;291:E1-8.
41. Cazarolli LH, Folador P, Moresco HH, Brighente IM, Pizzolatti MG, Silva FR. Stimulatory effect of apigenin-6-C-beta-L-fucopyranoside on insulin secretion and glycogen synthesis. Eur J Med Chem 2009;44:4668-73.
42. Cazarolli LH, Folador P, Pizzolatti MG, Mena Barreto Silva FR. Signaling pathways of kaempferol-3-neohesperidoside in glycogen synthesis in rat soleus muscle. Biochimie 2009;91:843-9.